Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson's Disease

Muñoz‐Delgado, Laura; Macías‐García, Daniel; Jesús, Silvia; Martín‐Rodríguez, Juan Francisco; Labrador‐Espinosa, Miguel A.; Jiménez-Jaraba, María Valle; Adarmes‐Gómez, Astrid; Carrillo, Fátima; Mir, Pablo

doi:10.1002/mds.28685

Cited by 41 publications

(43 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NLR has been reported to be higher in patients with Alzheimer's disease (AD) and PD than in HCs 15,16 . Recently, a meta-analysis showed that the NLR was higher in PD patients than in HCs 17 , which supports our results as PD and MSA are αsynucleinopathies.…”

Section: Discussionsupporting

confidence: 90%

High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy

Zhang

Cao

Hou

et al. 2022

npj Parkinsons Dis.

View full text Add to dashboard Cite

The neutrophil-to-lymphocyte ratio (NLR), an inflammatory marker, can predict the prognosis of neurodegenerative diseases. However, the significance of NLR for the prognosis of multiple system atrophy (MSA) has not been reported. We aimed to examine the prognostic significance of NLR in MSA. A total of 169 MSA patients and 163 matched healthy controls (HCs) were enrolled. MSA patients were divided into three groups according to the tertiles of their NLR. Kaplan–Meier survival analysis and Cox regression model were used to assessing the effect of NLR on survival. An independent validation cohort of 56 consecutive patients with probable MSA who met the inclusion criteria was included. The NLR was significantly higher in patients with MSA than that in HCs. The survival duration in patients with MSA in group 3 was shorter than that in patients in the other two groups (P = 0.013). In the multivariable Cox regression model, a higher NLR increased the risk of mortality in patients with MSA after adjusting for confounding factors (HR = 1.922, P = 0.035). Additionally, a higher NLR increased the risk of mortality in MSA with predominant cerebellar ataxia (MSA-C) (HR = 2.398, P = 0.033) and in men (HR = 3.483, P = 0.027). The concordance index for the multivariate Cox regression model was more than 0.7 both in the primary cohort and external validation cohort. Patients with MSA had a higher NLR than did HCs. A high NLR increased the risk of mortality with MSA, especially in MSA-C and in men.

show abstract

Section: Discussionsupporting

confidence: 90%

High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy

Zhang

Cao

Hou

et al. 2022

npj Parkinsons Dis.

View full text Add to dashboard Cite

show abstract

“…Previous evidences proved that neutrophil activation played an important role in various diseases, including cancer ( Rosell et al, 2021 ), cardiovascular disease ( Bonaventura et al, 2019 ), and Alzheimer’s disease ( Dong et al, 2019 ). And many studies demonstrated that, compared with healthy controls, PD patients had a high neutrophil count, which was consistent to the results of our study ( Ataç Uçar et al, 2017 ; Muñoz-Delgado et al, 2021 ). Our study showed that neutrophil activation could be an indicator of the inflammatory status and peripheral immune dysregulation in PD, but whether it is a cause or a consequence of PD progression remains unclear.…”

Section: Discussionsupporting

confidence: 93%

Integrative analysis of DNA methylation and gene expression data for the diagnosis and underlying mechanism of Parkinson’s disease

Ding

Liang²,

Guo³

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

BackgroundParkinson’s disease (PD) is the second most common progressive neurodegenerative disorder and the leading cause of disability in the daily activities. In the management of PD, accurate and specific biomarkers in blood for the early diagnosis of PD are urgently needed. DNA methylation is one of the main epigenetic mechanisms and associated with the gene expression and disease initiation of PD. We aimed to construct a methylation signature for the diagnosis of PD patients, and explore the potential value of DNA methylation in therapeutic options.Materials and methodsWhole blood DNA methylation and gene expression data of PD patients as well as healthy controls were extracted from Gene Expression Omnibus database. Next, differentially expressed genes (DEGs) and differentially methylated genes (DMGs) between PD patients and healthy controls were identified. Least absolute shrinkage and selection operator cox regression analysis was carried out to construct a diagnostic signature based on the overlapped genes. And, the receiver operating characteristic (ROC) curves were drawn and the area under the curve (AUC) was used to assess the diagnostic performance of the signature in both the training and testing datasets. Finally, gene ontology and gene set enrichment analysis were subsequently carried out to explore the underlying mechanisms.ResultsWe obtained a total of 9,596 DMGs, 1,058 DEGs, and 237 overlapped genes in the whole blood between PD patients and healthy controls. Eight methylation-driven genes (HIST1H4L, CDC42EP3, KIT, GNLY, SLC22A1, GCM1, INO80B, and ARHGAP26) were identified to construct the gene expression signature. The AUCs in predicting PD patients were 0.84 and 0.76 in training dataset and testing dataset, respectively. Additionally, eight methylation-altered CpGs were also identified to construct the CpGs signature which showed a similarly robust diagnostic capability, with AUCs of 0.8 and 0.73 in training dataset and testing dataset, respectively.ConclusionWe conducted an integrated analysis of the gene expression and DNA methylation data, and constructed a methylation-driven genes signature and a methylation-altered CpGs signature to distinguish the patients with PD from healthy controls. Both of them had a robust prediction power and provide a new insight into personalized diagnostic and therapeutic strategies for PD.

show abstract

“…NLR is an indicator of the inflammatory status, that is evaluated not only in infectious but also in neurodegenerative disorders such as Alzheimer’s disease (Dong et al 2019 ; Russell et al 2019 ). Elevated NLR was found in PD compared to healthy controls in a case–control study and confirmed in a subsequent meta-analysis of nine studies (Muñoz‐Delgado et al 2021 ). Late-onset PD is reported to have a higher NLR than early onset PD (Jin et al 2020 ).…”

Section: Blood-based Biomarkersupporting

confidence: 53%

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice

et al. 2022

View full text Add to dashboard Cite

The clinical presentation of Parkinson’s disease (PD) is both complex and heterogeneous, and its precise classification often requires an intensive work-up. The differential diagnosis, assessment of disease progression, evaluation of therapeutic responses, or identification of PD subtypes frequently remains uncertain from a clinical point of view. Various tissue- and fluid-based biomarkers are currently being investigated to improve the description of PD. From a clinician's perspective, signatures from blood that are relatively easy to obtain would have great potential for use in clinical practice if they fulfill the necessary requirements as PD biomarker. In this review article, we summarize the knowledge on blood-based PD biomarkers and present both a researcher’s and a clinician’s perspective on recent developments and potential future applications.

show abstract

Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson's Disease

Cited by 41 publications

References 37 publications

High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy

High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy

Integrative analysis of DNA methylation and gene expression data for the diagnosis and underlying mechanism of Parkinson’s disease

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice

Contact Info

Product

Resources

About